OncoMatch/Clinical Trials/NCT06560905
Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Is NCT06560905 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies 68Ga-PSMA for malignant melanoma.
Treatment: 68Ga-PSMA — This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Metastatic disease required
Demographics
Prior therapy
Cannot have received: lu-177 psma therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06560905 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior lu-177 psma therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages